Adalimumab biosimilar - CinnaGen

Drug Profile

Adalimumab biosimilar - CinnaGen

Alternative Names: Cinnora®

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CinnaGen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 06 Aug 2017 Cinnagen completes a phase I trial in Healthy volunteers in Iran (NCT03273192)
  • 22 Apr 2017 Cinnagen initiates enrolment in a phase I trial in Healthy volunteers in Iran (NCT03273192)
  • 04 Jan 2017 CinnaGen completes a phase III trial in Rheumatoid arthritis (Adjunctive treatment) in Iran (SC) (IRCT2015030321315N1) (NCT03172325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top